https://scholars.lib.ntu.edu.tw/handle/123456789/495012
標題: | Treating patients with ALK-positive non-small cell lung cancer: Latest evidence and management strategy | 作者: | BIN-CHI LIAO CHIA-CHI LIN JIN-YUAN SHIH CHIH-HSIN YANG |
公開日期: | 2015 | 卷: | 7 | 期: | 5 | 起(迄)頁: | 274-290 | 來源出版物: | Therapeutic Advances in Medical Oncology | 摘要: | Rearrangements in anaplastic lymphoma kinase (ALK) gene and echinoderm microtubule-associated protein-like 4 (EML4) gene were first described in a small portion of patients with non-small cell lung cancer (NSCLC) in 2007. Fluorescence in situ hybridization is used as the diagnostic test for detecting an EML4–ALK rearrangement. Crizotinib, an ALK inhibitor, is effective in treating advanced ALK-positive NSCLC, and the US Food and Drug Administration approved it for treating ALK-positive NSCLC in 2011. Several mechanisms of acquired resistance to crizotinib have recently been reported. Second-generation ALK inhibitors were designed to overcome these resistance mechanisms. Two of them, ceritinib and alectinib, were approved in 2014 for advanced ALK-positive NSCLC in the US and Japan, respectively. Heat shock protein 90 (Hsp90) inhibitors also showed activity against ALK-positive NSCLC. Here we review the recent development of crizotinib, ceritinib, alectinib and other second-generation ALK inhibitors as well as Hsp90 inhibitors. We also discuss management strategies for advanced ALK-positive NSCLC. ? 2015, SAGE Publications. All rights reserved. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84940190644&doi=10.1177%2f1758834015590593&partnerID=40&md5=7053701e25281c56ac55d36a953573e3 https://scholars.lib.ntu.edu.tw/handle/123456789/495012 |
ISSN: | 1758-8340 | DOI: | 10.1177/1758834015590593 | SDG/關鍵字: | 2 [[2 (isopropylsulfonyl)phenyl]amino] 4 [[2 methoxy 4 [4 (4 methyl 1 piperazinyl) 1 piperidinyl]phenyl]amino] 1,3,5 triazine; 6 amino 5 [1 (2,6 dichloro 3 fluorophenyl)ethoxy] n [4 (4 methyl 1 piperazinylcarbonyl)phenyl] 3 pyridazinecarboxamide; alectinib; anaplastic lymphoma kinase; anaplastic lymphoma kinase inhibitor; cep 37440; ceritinib; crizotinib; entrectinib; ganetespib; luminespib; onalespib; pf 06463922; retaspimycin; tsr 011; unclassified drug; [2 [[5 chloro 2 [[4 [4 (dimethylamino) 1 piperidinyl] 2 methoxyphenyl]amino] 4 pyrimidinyl]amino]phenyl]dimethylphosphine oxide; advanced cancer; cancer resistance; cancer therapy; central nervous system metastasis; fluorescence in situ hybridization; food and drug administration; human; Japan; non small cell lung cancer; priority journal; Review; treatment outcome |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。